Comparative efficacy of subcutaneous (CT-P13) and intravenous infliximab in adult patients with rheumatoid arthritis: a network meta-regression of individual patient data from two randomised trials

Table 4 Adjusted treatment differences at week 54

	Covariates	Week 54 — adjusted treatment difference, p-value
	Covariates	CT-P13 IV vs ref IFX IV	CT-P13 SC vs CT-P13 IV	CT-P13 SC vs Ref IFX IV	CT-P13 SC vs IFX IV
Change from baseline in DAS28-CRP score (95% CI)	Race, baseline DAS28-CRP, Anti-CPP, BMI, HAQ-DI, PADA	− 0.089 (− 0.299; 0.121), p = 0.4052	− 0.852 (− 1.097; − 0.607), p < 0.0001	− 0.941 (− 1.204; − 0.678), p < 0.0001	− 0.876 (− 1.119; − 0.633), p < 0.0001
Change from baseline in CDAI score (95% CI)	Race, baseline CDAI, HAQ-DI, PADA	− 1.014 (− 2.796; 0.768), p = 0.2645	− 6.283 (− 8.686; − 3.880), p < 0.0001	− 7.297 (− 9.831; − 4.763), p < 0.0001	− 6.484 (− 9.026; − 3.942), p < 0.0001
Change from baseline in SDAI score (95% CI)	Race, baseline SDAI, HAQ-DI, PADA	− 1.218 (− 3.119; 0.683), p = 0.2093	− 7.062 (− 9.318; − 4.806), p < 0.0001	− 8.279 (− 10.611; − 5.947), p < 0.0001	− 7.302 (− 9.711; − 4.893), p < 0.0001

Anti-CCP anti-cyclic citrullinated peptide, BMI body mass index, CDAI Clinical Disease Activity Index, CRP C-reactive protein, DAS28-CRP 28-joint Disease Activity Score based on C-reactive protein, HAQ Health Assessment Questionnaire–Disability Index, IFX infliximab, IV intravenous, PADA Patient Global Assessment of Disease Activity, Ref reference, SC subcutaneous, SDAI Simplified Disease Activity Index

ISSN: 1478-6362